Evaluating a new medication for tardive dyskinesia

A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetic Characteristics of Multiple Doses of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

This study is testing a new medication for tardive dyskinesia to see if it helps people aged 18 to 65 who have had symptoms from their medication for at least three months.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Ages: 18 Years to 64 Years
• Sex: All
• Sponsor: Luye Pharma Group Ltd. (Industry-sponsored)
• Locations: 1 site (Shanghai)
• Trial ID: NCT06731868 on ClinicalTrials.gov

What this trial studies

This clinical trial is a multicenter, randomized, double-blind, placebo-controlled study designed to assess the safety, tolerability, and preliminary efficacy of LPM3770164 sustained-release tablets in patients diagnosed with tardive dyskinesia. Participants will receive varying doses of the medication or a placebo to determine its pharmacokinetics and overall effectiveness. The study aims to include patients aged 18 to 65 who have experienced medication-induced tardive dyskinesia for at least three months. The trial will monitor participants closely to evaluate their response to the treatment over the course of the study.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 65 with a diagnosis of medication-induced tardive dyskinesia lasting at least three months.

Not a fit: Patients with tardive dyskinesia symptoms lasting less than three months or those outside the age range may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the management of tardive dyskinesia symptoms in affected patients.

How similar studies have performed: Other studies have explored treatments for tardive dyskinesia, but the specific approach of using LPM3770164 is novel and has not been widely tested.

Eligibility criteria

Inclusion Criteria:

1. Subject who voluntarily participate in and sign the informed consent form;
2. Male or female subjects aged ≥ 18 years and \< 65 years;
3. Body mass index (BMI) 18.5 \~ 38.0 kg/m2 (including boundary value);
4. Subjects with a past diagnosis of schizophrenia, schizoaffective disorder, bipolar and related disorders, depressive disorders based on medical history, and stable for at least 1 month;
5. Subjects who have been diagnosed with medication-induced TD, and whose symptoms have lasted for at least 3 months according to the DSM-5; and TD is assessed as moderate or severe (AIMS Item 8 score ≥3);
6. Medications for schizophrenia, schizoaffective disorder, bipolar and related disorders, depressive disorders and extrapyramidal reactions should be kept dose stable for at least 1 month (benzodiazepines should stable at least 14 days, Long-acting injection should stable for at least 3 months);
7. Females of childbearing potential have a negative pregnancy test. Male and female patients of childbearing potential and their spouses/partners agree to not plan to become pregnant (including the plan for sperm and egg donation) and to use effective contraceptive measures throughout the study and for at least 1 month after the last dose of the study drug.

Exclusion Criteria:

1. Has comorbid abnormal involuntary movement(s) that is more prominent than TD as judged by the investigator;
2. Has Simpson-Angus Scale (SAS) score≥ 3 on two or more items other than items 8 and 10;
3. Currently in the acute phase of mental disorder or severe psychiatric symptoms, unable to cooperate with the treatment and assessment, as judged by the investigator;
4. Has a history of suicide attempt or Question 4 or Question 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS) as "Yes" within the past 6 months;
5. Has a history of neuroleptic-related malignant syndrome;
6. Has diagnosed with malignant tumor within 3 years before randomization;
7. Has a history of long QT syndrome or tachyarrhythmia within 3 years before randomization;
8. Electrocardiogram QTcF \> 450 ms, or other clinically significant ECG findings in the opinion of the investigator;
9. Patients with significant abnormal liver and kidney function indicators, meeting any of the following criteria: serum creatinine \> 1.5 × upper limit of normal (ULN); serum alanine transaminase (ALT) or aspartate transaminase (AST) \> 2.5 × ULN; total bilirubin \> 1.5 × ULN;
10. Has active, severe and unstable cerebrovascular, liver, kidney, endocrine, cardiovascular, gastrointestinal, respiratory, or metabolic disorders within 30 days prior to screening, in the judgment of the investigator, would interfere with the patient's ability to participate in the trial;
11. Any surgical condition or condition that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects participating in the trial, such as but not limited to history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcers, gastrointestinal bleeding;
12. Has a known history of allergy to any component of the investigational product or similar drugs, or allergic constitution;
13. Has a positive human immunodeficiency virus antibody (HIV-Ab) and syphilis;
14. Has a positive urine drug screen;
15. Patients diagnosed with substance-related and addictive disorders (except tobacco- or caffeine-related disorders) within 6 months prior to the screening visit;
16. Has participated in any clinical trials of drugs (excluding vitamins and minerals) within 3 months prior to the screening visit;
17. Patients who previously received deep brain stimulation (DBS), or received electroconvulsive therapy (ECT) or other physical therapy within 1 month prior to the screening visit;
18. Patients who use of strong inducers or inhibitors of CYP3A4 within 14 days or 5 half-lives, whichever is longer, prior to randomization;
19. Known history of a nonresponder to tetrabenazine, deutetrabenazinen, or valbenazine for the treatment of TD;
20. Patients who have been injected with botulinum toxin in the past 3 months;
21. Patients who have used the prohibited drugs in the past 1 month;
22. Nursing mothers;
23. For patients with schizophrenia and schizoaffective disorder, has a total PANSS score \> 80, and/or a total CDSS score \> 10;
24. For patients with bipolar and related disorders or depressive disorders, has a history of rapid cycling, or a total MADRS score \> 22, or a total YMRS score \> 12;
25. Other conditions judged by the investigator as unsuitable for participating in the trial.

Where this trial is running

Shanghai

• Shanghai Mental Health Center — Shanghai, China (Recruiting)

Study contacts

• Study coordinator: Hufang Li

Conditions Tardive Dyskinesia